Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy
NCT07237269Phase 2Recruiting
- Sponsor
- University of Nebraska
- Start
- Sep 2026
- Primary completion
- Apr 2033
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in prostate cancer (PCa), sponsored by University of Nebraska. Started Sep 2026; status: recruiting.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07237269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237269.